Acelyrin, Inc. (SLRN)
NASDAQ: SLRN · Real-Time Price · USD
2.600
-0.040 (-1.52%)
At close: Mar 28, 2025, 4:00 PM
2.355
-0.245 (-9.42%)
Pre-market: Mar 31, 2025, 8:00 AM EDT
Company Description
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines.
The company’s lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R for the treatment of Thyroid Eye Disease (TED), which is in Phase 2.
Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.
Acelyrin, Inc.
| Country | United States |
| Founded | 2020 |
| IPO Date | May 5, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 83 |
| CEO | Mina Kim |
Contact Details
Address: 4149 Liberty Canyon Road Agoura Hills, California 91301 United States | |
| Phone | 805 456 4393 |
| Website | acelyrin.com |
Stock Details
| Ticker Symbol | SLRN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001962918 |
| CUSIP Number | 00445A100 |
| ISIN Number | US00445A1007 |
| Employer ID | 85-2406735 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mina Kim J.D. | Chief Executive Officer and Director |
| Dr. Shephard Mpofu M.D. | Chief Medical Officer |
| Tyler Marciniak | Vice President of Investor Relations, Communications and Corporate Operations |
| K. Amar Murugan J.D. | Chief Legal Officer |
| Kelly Chow | Chief People Officer |
| Kenneth A. Lock | Chief Commercial Officer |
| Patricia A. Turney | Chief Technical Operations Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 25, 2025 | 425 | Filing |
| Mar 19, 2025 | 425 | Filing |
| Mar 19, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 19, 2025 | 10-K | Annual Report |
| Mar 18, 2025 | 425 | Filing |
| Mar 14, 2025 | 144 | Filing |
| Mar 13, 2025 | 8-A12B | Registration of securities |
| Mar 13, 2025 | 425 | Filing |
| Mar 13, 2025 | 8-K | Current Report |
| Mar 12, 2025 | SCHEDULE 13D/A | Filing |